BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, March 18th and determining how the s Read More >>

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/18/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/18/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/11/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on November 30, 2009 at $2.54. In approximately 3 months, Keryx Biopha Read More >>

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/11/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the Read More >>

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, March 11th and determining how the s Read More >>

InvestorSoup.com announces an investment report featuring Keryx Biopharmaceuticals Inc. (Nasdaq:KERX). The report includes financial, comparative a Read More >>

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/11/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/11/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the C Read More >>

SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on November 30, 2009 at $2.54. In approximately 3 months, Keryx Biopha Read More >>

Canadin biopharmaceutical company AEterna Zentaris has received a positive opinion for orphan medicinal product designation for its compound perifosine from Read More >>

Æterna Zentaris Inc. (NASDAQ: AEZS, TSX:AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocri Read More >>

Æterna Zentaris Inc. (NASDAQ: AEZS, TSX:AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinol Read More >>

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/11/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

Analyst Upgrades for 2/25/2010... Big Lots (NYSE:BIG) upgraded to Overweight from Neutral, $38 target, at JP Morgan... Broadcom (NASDAQ:BRCM) initi Read More >>

Research and Markets (http://www.researchandmarkets.com/research/40f57a/company_financials) has announced the addition of the "Company Financials: Read More >>

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a co Read More >>

InvestorSoup.com announces an investment report featuring Keryx Biopharmaceuticals Inc. (Nasdaq:KERX). The report includes financial, comparative a Read More >>

Keryx Biopharmaceuticals has reached agreement with the FDA regarding a special protocol assessment, or SPA, on the design of the Phase III trial for its PI Read More >>

Keryx Biopharmaceuticals Inc (KERX)

Expected next earnings release:

Announcement date: 3/11/2010 - After Market

Earnings Quarter: Q4
          
            Read More
            >>
          
        

Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr. Johanna Bendell, Director, GI Onco Read More >>

Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr. Johanna Bendell, Director, GI Onco Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regar Read More >>

SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on November 30, 2009 at $2.54. In approximately 2 months, Keryx Biopha Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 12 Read More >>

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a commu Read More >>

Data Demonstrating a 35% Overall Response Rate with a Median Progression-Free Survival of 12.6 Months in Patients with Relapsed or Relapse Read More >>

Data Demonstrating a 35% Overall Response Rate with a Median Progression-Free Survival of 12.6 Months in Patients with Relapsed or Relapsed Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Ph Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq SC : KERX) will host a conference call regarding to Discuss KRX-0401 (Perifosine) Clinical Deve Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will conduct a conference call to discuss the updated Phase 2 results on the clinical activity of KR Read More >>

Liberty Analytics Co., a leading provider of large ,small - and micro-cap independent investment research, today initiated coverage on K Read More >>

Brean Murray, Carret & Co. will hold its 2010 Healthcare 1x1 Conference on Monday, March 1st in Boston at the Hilton Financial District. The Read More >>

SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on November 30, 2009 at $2.54. In approximately 2 months, Keryx Biopha Read More >>

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression Read More >>

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression a Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) yesterday reported updated results on the clinical activity of KRX-0401 (perifosine), the Company's Read More >>

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a commu Read More >>

Updated results from Phase 2 clinical trial of perifosine in combination with capecitabine for the treatment of metastatic colon cancer to Read More >>

Updated results from Phase 2 clinical trial of perifosine in combination with capecitabine for the treatment of metastatic colon cancer to Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that updated results from its Phase 2 clinical trial of KRX-0401 (perifosine) in com Read More >>

SmarTrend, the proprietary pattern recognition system, has made available a free sample copy of our premium research report on (NASDAQ:KER Read More >>

SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on November 30, 2009 at $2.54. In approximately 1 month, Keryx Biophar Read More >>

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the J Read More >>

1/5/2010- Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) said it agreed with regulators about the design of clinical studies for its drug candidate Read More >>